Faron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

Faron Pharmaceuticals Oy (LON:FARN) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 144.08 and traded as low as GBX 55.63. Faron Pharmaceuticals Oy shares last traded at GBX 58, with a volume of 131,836 shares changing hands.

Faron Pharmaceuticals Oy Price Performance

The company’s 50-day moving average price is GBX 141.88 and its 200-day moving average price is GBX 173.50. The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The company has a market cap of £66.71 million, a P/E ratio of -2.16 and a beta of 0.36.

Insider Transactions at Faron Pharmaceuticals Oy

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of Faron Pharmaceuticals Oy stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total value of £7,280. Company insiders own 4.05% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.